EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating personalized circulating tumor DNA detection for early‐stage lung cancer

Haihua Huang, Zhentian Kai iD, Yuchen Wang, Xiaomiao Zhang, Jin Wang, Wei Zhang, Qian Xue, Hang Zhang, Hansong Jin, Peize Meng, Shuilong Zhang, Yueyue Yang und 7 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Haihua Huang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai First People's Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) has been widely used as a minimally invasive biomarker in clinical routine. However, a number of factors such as panel design, sample quality, patients' disease stages are known to influence ctDNA detection sensitivity. In this study, we systematically evaluated common factors associated with the variability of ctDNA detection in plasma and investigated ctDNA abundance in bronchoalveolar lavage (BAL). Whole exome profiling was conducted on 61 tumor tissue samples to identify tumor‐specific variants, which were then used to design personalized assay MarRyDa® for ctDNA detection. DNA extracted from BAL fluid and plasma were genotyped using MarRyDa® platform. Our analysis showed that histological subtypes and disease stages had significant differences in ctDNA detection rate. Furthermore, we found that DNA purified from BAL supernatants contains the highest levels of ctDNA compared with BAL precipitates and plasma; therefore, utilizing BAL supernatants for tumor detection might provide additional benefits. Finally, we demonstrated that tumor cellularity played significant roles in the design of personalized ctDNA panel which eventually impacts ctDNA detection sensitivity. We suggest setting a flexible criteria for sample quality control and utilization of BAL might benefit more patients in clinics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALung NeoplasmsBiomarkers, TumorHumansFemaleBronchoalveolar Lavage FluidMalePrecision MedicineNeoplasm StagingEarly Detection of CancerMiddle AgedAged

Stichwörter der Autor:innen

biomarkersbiotechnologygenomicslung cancermolecular diagnosis

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai First People's Hospital, Shanghai, China.
  • Department of research and Development, Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., Shanghai, China.

ORCID-Profile: Zhentian Kai

Zitieren

APA

Huang, H., Kai, Z., Wang, Y., Zhang, X., Wang, J., Zhang, W., Xue, Q., Zhang, H., Jin, H., Meng, P., Zhang, S., Yang, Y., Yang, H., Liang, W., Zha, G., Luo, P., Xu, Y., Shi, W., & Ruan, Z. (2024). Evaluating personalized circulating tumor DNA detection for early‐stage lung cancer. Cancer Medicine. https://doi.org/10.1002/cam4.6817

Vancouver

Huang H, Kai Z, Wang Y, Zhang X, Wang J, Zhang W, et al. Evaluating personalized circulating tumor DNA detection for early‐stage lung cancer. Cancer Medicine. 2024. doi:10.1002/cam4.6817

BibTeX
@article{Huang2024,
  author = {Huang, Haihua and Kai, Zhentian and Wang, Yuchen and Zhang, Xiaomiao and Wang, Jin and Zhang, Wei and Xue, Qian and Zhang, Hang and Jin, Hansong and Meng, Peize and Zhang, Shuilong and Yang, Yueyue and Yang, Honghua and Liang, Wanning and Zha, Guangbing and Luo, Peng and Xu, Yan and Shi, Weiwei and Ruan, Zheng},
  title = {Evaluating personalized circulating tumor DNA detection for early‐stage lung cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6817}
}
Kostenlos starten →